EGFR plays a key oncogenic role in IP-SCC 4,5, as study has shown identical EGFR genotypes in SNIP and paired IP-SCC, with EGFR inhibitors proving effective in IP-SCC-derived cell lines 4. The gene discussed is EGFR; the disease is incontinentia pigmenti.